迪瑞医疗科技股份有限公司 第六届董事会第四次临时会议决议公告 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-041 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 迪瑞医疗科技股份有限公司（以下简称"公司"）第六届董事会第四次临时 会议（以下简称"本次会议"）于 2025 年 09 月 28 日在公司以现场结合通讯方式 召开，本次会议由董事长郭霆先生主持，应出席公司会议的董事 9 人，实际出席 公司会议的董事 9 人，公司监事、高级管理人员列席会议。根据《公司章程》的 规定，本次会议通知于 2025 年 09 月 25 日以电子邮件送达方式发出，会议召开 符合《中华人民共和国公司法》、《公司章程》的规定，会议合法有效。 二、会议审议情况 与会董事经认真审议，以现场结合通讯表决方式审议通过了如下决议： 1、审议并一致通过《关于变更公司经营范围的议案》 公司结合自身业务实际情况，变更经营范围及对《公司章程》相应条款作出 修订，本次变更不会导致公司主营业务发生变更。 具体内容详见巨潮资讯网（www.cninfo.com.cn）《关 ...

Core Viewpoint - The recent management overhaul at Di Rui Medical is a response to significant revenue declines and losses, marking a critical moment for the company within the healthcare sector under China Resources Holdings [1][4][10]. Company Performance - Di Rui Medical reported a revenue of 351 million yuan for the first half of 2025, a decrease of 60.1% year-on-year, and a net profit loss of 28 million yuan, representing a 117.1% decline [4][2]. - The company experienced its first net profit loss since its listing in 2014, attributed to macroeconomic slowdowns, ongoing centralized procurement policies, and intensified industry competition [4][5]. - The company's operating cash flow was negative 8.43 million yuan, a 97.1% decrease compared to the previous year [4]. Management Changes - Following a significant drop in performance, Di Rui Medical underwent a complete management reshuffle, with all top executives replaced, including the chairman and general manager [1][7]. - The new management team, primarily sourced from China Resources Pharmaceutical Group, aims to implement strategic reviews and business optimizations [9][7]. Industry Context - China Resources Holdings has been actively expanding in the healthcare sector, with ten listed platforms covering various fields, but has faced challenges in the medical device segment, particularly with Di Rui Medical [1][11]. - The medical device industry is undergoing transformation due to centralized procurement and cost control measures, impacting many companies, including Di Rui Medical, which has struggled to maintain profitability [4][5][14]. Future Strategies - Di Rui Medical plans to focus on three core areas: expanding overseas markets, accelerating domestic equipment installations, and optimizing supply chains to enhance efficiency [14][15]. - The company aims to recover from its current downturn through a series of reforms and strategic adjustments, although the effectiveness of these measures remains to be seen [9][15].

Core Viewpoint - The recent management overhaul at Dirui Medical, led by the China Resources Group, aims to address the company's significant performance challenges and potentially turn around its declining business [1][2][5]. Management Changes - Dirui Medical has undergone a significant management restructuring, with new appointments including Guo Ting as chairman and Lang Tao as general manager, both from China Resources Pharmaceutical Group [2][3]. - The new management team is focusing on strategic review and optimization based on industry trends and operational realities, with an emphasis on enhancing the company's strategic planning and execution [2]. Financial Performance - Dirui Medical reported a revenue of 351 million yuan for the first half of 2025, a decrease of 60.07% year-on-year, and a net loss of 28.31 million yuan, marking the first half-year loss since its listing [5]. - The company attributed its poor performance to factors such as macroeconomic slowdown, ongoing centralized procurement policies, and increased industry competition, compounded by asset impairment provisions [5][6]. - In 2024, Dirui Medical's annual revenue was 1.218 billion yuan, down 11.63% year-on-year, with a net profit of 142 million yuan, a decline of 48.5% [5]. Product Structure and Market Strategy - Dirui Medical's product mix shows an imbalance, with reagents accounting for 57% of revenue and instruments for 42% in the first half of 2025, compared to competitors with higher reagent revenue proportions [6]. - The company plans to focus on three core areas in the second half of 2025: expanding international markets, accelerating domestic equipment installation, and optimizing the supply chain to enhance operational efficiency [6]. Future Outlook - The effectiveness of the new management team in reversing Dirui Medical's performance decline remains to be seen, as the company navigates its current challenges [7].

Group 1 - The company, DiRi Medical, announced the approval of a change in its Medical Device Production License by the Jilin Provincial Drug Administration [1] - The changes primarily involve the alteration of the legal representative and the person in charge of the company, with Lang Tao being appointed as the new legal representative and responsible person [1]

Core Viewpoint - The company, Dirui Medical, has recently obtained approval from the Jilin Provincial Drug Administration for changes to its Medical Device Manufacturing License, specifically regarding the change of its legal representative and corporate responsible person to Lang Tao [1] Group 1 - The approval involves a change in the legal representative and corporate responsible person of the company [1] - The new legal representative and corporate responsible person is Lang Tao [1]

关于变更医疗器械生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-040 迪瑞医疗科技股份有限公司 特此公告。 迪瑞医疗科技股份有限公司董事会 2025 年 09 月 11 日 迪瑞医疗科技股份有限公司（以下简称"公司"）于近日取得了吉林省药品 监督管理局批准变更的《医疗器械生产许可证》（许可证编号：吉药监械生产许 20170005 号），本次主要涉及法定代表人、企业负责人的变更，公司医疗器械生 产许可证法定代表人和企业负责人变更为郎涛。 除上述变更外，公司医疗器械生产许可证记载的其他内容未发生变化。医疗 器械生产许可证记载的其他内容可详见公司于 2025 年 2 月 5 日披露于巨潮资讯 网（www.cninfo.com.cn）上的相关公告。 ...

Group 1 - The core point of the announcement is that Guangdong Hengjian International Investment Co., Ltd., a shareholder holding more than 5% of the shares, has completed its share reduction plan without executing any sales during the designated period [1] - As of the announcement date, Hengjian International holds 33,123,600 shares of Dirui Medical Technology Co., Ltd., representing 12.15% of the company's total share capital [1] - The share reduction plan complies with various relevant laws and regulations, including the Company Law of the People's Republic of China and the Securities Law of the People's Republic of China [1]

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-039 迪瑞医疗科技股份有限公司 关于持股 5%以上股东减持股份计划实施期限届满的公告 持股 5%以上的股东广东恒健国际投资有限公司保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 截至本公告披露日，恒健国际本次减持计划实施期限已届满，本次减持计划 期间内未减持其持有的公司股份。恒健国际持有公司股份数量为 33,123,600 股， 占公司目前总股本比例为 12.15%。 二、其他相关说明 1、恒健国际本次减持计划符合《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司收购管理办法》《深圳证券交易所创业板股票上市规则》《上 市公司股东减持股份管理暂行办法》《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减持股份》等法律、法规及规范性文件的 规定。 2、上述股东本次减持公司股份事项已按照相关规定进行了预披露，本次减 持符合已披露的减持计划，本次减持计划期间未减持公司股份，不存在违规情形。 截至目前，本次减持计划实施期限已届满。 三、备查文件 恒健国际出具的《关于减持迪瑞医疗股份计 ...

Group 1: Financial Performance - The company experienced a loss in the first half of 2025 due to multiple factors including macroeconomic slowdown, ongoing procurement policies, and intensified industry competition [2] - Total expenses for sales, management, and R&D decreased by 16% year-on-year, enhancing operational efficiency [5] - Cash flow increased by 97.07% year-on-year, indicating improved financial health [6] Group 2: International Market Strategy - The international business grew by 24% year-on-year, with significant growth in key markets such as India, Asia-Pacific, and Turkey [3] - The company has over 20 years of experience in overseas operations, focusing on local management to enhance brand value [3] Group 3: Strategic Adjustments - A new management team with industry backgrounds is conducting a strategic review to enhance the company's operational effectiveness [4] - The company aims to focus on three core areas in the second half of 2025: expanding international markets, accelerating domestic equipment installation, and optimizing the supply chain [2] Group 4: R&D and Technological Advancements - The company launched a fully automated urine analyzer, achieving high precision in identifying 50 types of cells [6] - Progress in AI integration within medical technology is being pursued, with advancements in intelligent recognition systems for medical imaging [7] Group 5: Cost Management - Financial expenses saw a significant reduction due to improved fund management and currency risk control, with interest income increasing by approximately 1.391 million [6] - The company implemented precise resource allocation in marketing, leading to enhanced cost efficiency [5]

Core Insights - The company, Dirui Medical, reported a significant decline in financial performance for the first half of 2025, with total revenue of 351 million yuan, a year-on-year decrease of 60.07% [1] - The net profit attributable to shareholders was -28.31 million yuan, reflecting a year-on-year decline of 117.13% [1] - The company's gross margin decreased to 38.85%, down 9.85% year-on-year, while the net margin turned negative at -8.07%, a drop of 142.92% [1] Financial Performance Summary - Total revenue for 2025 was 351 million yuan, down from 878 million yuan in 2024, a decrease of 60.07% [1] - Net profit attributable to shareholders was -28.31 million yuan, compared to a profit of 16.5 million yuan in 2024, a decline of 117.13% [1] - The company's operating expenses, including financial, sales, and administrative costs, accounted for 30.61% of total revenue, an increase of 83.13% year-on-year [1] - The gross margin was 38.85%, down from 43.10% in 2024, a decrease of 9.85% [1] - The net margin was -8.07%, compared to 18.81% in 2024, a decline of 142.92% [1] Cash Flow and Debt Analysis - The net cash flow from operating activities showed a significant improvement, with a change of 97.07% due to better sales collection compared to the previous year [3] - The company’s interest-bearing debt increased to 550 million yuan, a rise of 70.00% from 324 million yuan in 2024 [1] - The net increase in cash and cash equivalents was up by 77.99%, influenced by the net cash flow from operating activities [4] Business Model and Market Strategy - The company relies heavily on research and development as well as marketing to drive its performance [4] - In the first quarter of 2025, the company focused on enhancing the installation of instruments and increasing reagent sales in the domestic market, completing over 400 instrument installations [4] - The international market strategy has been adjusted to focus on Southeast Asia and key countries along the Belt and Road Initiative, with minimal impact from uncontrollable factors [4]